Literature DB >> 19859065

Engineering lymphocyte subsets: tools, trials and tribulations.

Carl H June1, Bruce R Blazar, James L Riley.   

Abstract

Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.

Entities:  

Mesh：

Year:  2009        PMID： 19859065      PMCID： PMC3412112          DOI： 10.1038/nri2635

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


  161 in total

Review 1.  The lineage decisions of helper T cells.

Authors:  Kenneth M Murphy; Steven L Reiner
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

Review 2.  Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.

Authors:  Marina Ferrarini; Elisabetta Ferrero; Lorenzo Dagna; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Trends Immunol       Date:  2002-01       Impact factor: 16.687

3.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors:  John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

Review 4.  Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.

Authors:  Richard D Lopez
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

Authors:  Marcela V Maus; Anna K Thomas; Debra G B Leonard; David Allman; Kathakali Addya; Katia Schlienger; James L Riley; Carl H June
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

6.  Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

Authors:  S M Tahir; O Cheng; A Shaulov; Y Koezuka; G J Bubley; S B Wilson; S P Balk; M A Exley
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

7.  Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

Authors:  Linda Mesler Muul; Laura M Tuschong; Sherry Lau Soenen; G Jayashree Jagadeesh; W Jay Ramsey; Zhifeng Long; Charles S Carter; Elizabeth K Garabedian; Melinna Alleyne; Margaret Brown; Wendy Bernstein; Shepherd H Schurman; Thomas A Fleisher; Susan F Leitman; Cynthia E Dunbar; R Michael Blaese; Fabio Candotti
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

8.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Authors:  Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

9.  Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells.

Authors:  Yoshiyuki Tanaka; Steven F Dowdy; David C Linehan; Timothy J Eberlein; Peter S Goedegebuure
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

Review 10.  T-cell-receptor gene therapy.

Authors:  Ton N M Schumacher
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106
View more
  91 in total

1.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors:  Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

3.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

Review 4.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

5.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

Review 6.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

Review 7.  Adoptive T cell therapy of cancer.

Authors:  Malcolm K Brenner; Helen E Heslop
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

8.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

9.  Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Joseph G Crompton; Anthony J Leonardi; Tori N Yamamoto; Smita S Chandran; Robert L Eil; Madhusudhanan Sukumar; Suman K Vodnala; Jinhui Hu; Yun Ji; David Clever; Mary A Black; Devikala Gurusamy; Michael J Kruhlak; Ping Jin; David F Stroncek; Luca Gattinoni; Steven A Feldman; Nicholas P Restifo
Journal:  JCI Insight       Date:  2017-12-07

Review 10.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.